Prospects and Trends in the Brazilian Market for Biologically Sourced Products
The aim of this paper was to select the most interesting Brazilian biopharmaceuticals, with the best market opportunity for production. The biopharmaceuticals filgrastim, infliximab, somatropin, imiglucerase, betainterferon and factor VIII were selected because they are not produced in Brazil and th...
Guardado en:
| Autores principales: | , , |
|---|---|
| Lenguaje: | English |
| Publicado: |
Universidad Alberto Hurtado. Facultad de Economía y Negocios
2012
|
| Materias: | |
| Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0718-27242012000300005 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | The aim of this paper was to select the most interesting Brazilian biopharmaceuticals, with the best market opportunity for production. The biopharmaceuticals filgrastim, infliximab, somatropin, imiglucerase, betainterferon and factor VIII were selected because they are not produced in Brazil and thus could increase the technological capacity of domestic production. The use of a data mining tool facilitated the results achieved here, using the patents deposited in several banks worldwide as the source information. The prospects and trends of producing biopharmaceuticals in Brazil are of great interest to the country to establish a competitive industry and reduce the vulnerability of the National Health System, such as display windows of opportunity, showing the possibility of moving towards the production of biopharmaceuticals. |
|---|